Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
References (32)
- et al.
Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans
Am J Cardiol.
(1993) - et al.
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy
Am J Cardiol.
(1995) - et al.
Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia
Am J Cardiol.
(1994) - et al.
Fluvastatin, with and without niacin, for hypercholesterolemia
Am J Cardiol.
(1994) Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol Levels. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
JAMA
(1993)- et al.
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
NEJM.
(1990) - et al.
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
JAMA
(1990) - et al.
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up
JAMA
(1990) - et al.
The value of lowering cholesterol after myocardial infarction
NEJM
(1990) - et al.
Effect of partial ileal bypass surgery on mortality, morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
NEJM.
(1990)
Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel
JAMA.
(1993)
Telephone contacts do not improve compliance to niacin or bile acid sequestrants
Ann Pharm.
(1994)
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
JAMA
(1984)
Clofibrate, niacin in coronary heart disease. The Coronary Drug Project Research Group
JAMA.
(1975)
Combination drug therapy for hypercholesterolemia: the trade-off between cost and simplicity
Arch Int Med.
(1993)
Cited by (168)
COACH trial: A randomized controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers: Rationale and design
2011, Contemporary Clinical TrialsCitation Excerpt :Despite well-publicized guidelines on the appropriate management of cardiovascular disease (CVD) and type 2 diabetes, implementation of risk-reducing practices remains poor. In spite of the known benefit of lowering low density lipoprotein cholesterol (LDL-C) levels below 100 mg/dl in persons with existing heart disease [1–5], as many as 50–70% of eligible CVD patients are not placed on lipid-lowering therapy by their providers and from 20 to 80% of patients do not achieve the goals of therapy [6–9]. The benefits of controlling high blood pressure (HBP) are well established yet national rates of HBP control have not improved significantly from a national average of 29–31% despite decades of provider and patient education [10–12].
Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia
2009, Journal of Nutritional BiochemistryEffects of D-003, a mixture of high-molecular-weight sugar cane wax acids, on lipid peroxidation markers in older individuals: A randomized, double-blind, placebo-controlled study
2008, Current Therapeutic Research - Clinical and ExperimentalPreventing cardiovascular disease among Canadians: What are the potential benefits of treating hypertension or dyslipidemia?
2007, Canadian Journal of Cardiology
Copyright © 1996 Published by Elsevier Inc.